摘要
冠心病是21世纪严重危害人类健康的常见病,经皮腔内冠状动脉介入治疗(PCI)是目前冠心病血运重建的主要方法,尽管随着雷帕霉素、紫杉醇、西莫罗斯等药物涂层支架的临床应用,有效降低了支架内再狭窄的发生率。然而药物涂层支架(DES)亦存在支架内血栓形成的风险,抗PCI术后支架内再狭窄药物的研究开发依然是目前PCI研究中的核心问题。昆明山海棠(THH)具有抗炎、抗免疫、抑制平滑肌细胞增殖和抑制损伤血管新生内膜形成等作用,在PCI术后再狭窄中具有一定的应用前景。
Coronary heart disease is a common disease that seriously endangers human health in twenty-first century.Percutaneous coronary intervention(PCI) is the main method of revascularization of coronary heart disease,in spite of the clinical application of drug eluting stents,such as rapamycin,paclitaxel and Simo Ross,the incidence of stent restenosis was decreased.However,the drug coating stent also has the risk of stent thrombosis.The research and development of PCI stent restenosis drug is still the core issue in PCI research.THH has anti-inflammatory,anti immunity,inhibiting the proliferationof smooth muscle cells and inhibiting the formation of vascular intimal hyperplasia,and so on,and has a certain application prospects in the restenosis after PCI.
出处
《临床医学》
CAS
2017年第3期119-121,共3页
Clinical Medicine
基金
云南省应用基础研究计划项目(201401UH00288)~~
关键词
昆明山海棠
经皮腔内冠状动脉介入治疗
再狭窄
Tripterggium hupoglaucum hutch
Percutaneous coronary intervention
Restenosis
